Osteoprotegerin and mortality in type 2 diabetic patients

Henrik Reinhard; Maria Stenkil Lajer; Mari-Anne Gall; Lise Tarnow; Hans-Henrik Parving; Lars Melholt Rasmussen; Peter Rossing

doi:10.2337/dc10-0858

Osteoprotegerin and mortality in type 2 diabetic patients

Henrik Reinhard, Maria Stenkil Lajer, Mari-Anne Gall, Lise Tarnow, Hans-Henrik Parving, Lars Melholt Rasmussen, Peter Rossing

50 Citationer (Scopus)

Abstract

Plasma osteoprotegerin (OPG) is an emerging strong and independent predictor of cardiovascular disease (CVD) in high-risk populations. OPG is a bone-related glycopeptide produced by vascular smooth muscle cells, and increased plasma OPG levels may reflect arterial vascular damage. We aimed to investigate the prognostic value of OPG in relation to all-cause and cardiovascular mortality in a cohort of type 2 diabetic patients.

Originalsprog	Engelsk
Tidsskrift	Diabetes Care
Vol/bind	33
Udgave nummer	12
Sider (fra-til)	2561-6
Antal sider	6
ISSN	0149-5992
DOI	https://doi.org/10.2337/dc10-0858
Status	Udgivet - 1 dec. 2010

Adgang til dokumentet

10.2337/dc10-0858

Citationsformater

@article{e4d3ec44133b45c1afe82e5539342ba4,

title = "Osteoprotegerin and mortality in type 2 diabetic patients",

abstract = "Plasma osteoprotegerin (OPG) is an emerging strong and independent predictor of cardiovascular disease (CVD) in high-risk populations. OPG is a bone-related glycopeptide produced by vascular smooth muscle cells, and increased plasma OPG levels may reflect arterial vascular damage. We aimed to investigate the prognostic value of OPG in relation to all-cause and cardiovascular mortality in a cohort of type 2 diabetic patients.",

author = "Henrik Reinhard and Lajer, {Maria Stenkil} and Mari-Anne Gall and Lise Tarnow and Hans-Henrik Parving and Rasmussen, {Lars Melholt} and Peter Rossing",

year = "2010",

month = dec,

day = "1",

doi = "10.2337/dc10-0858",

language = "English",

volume = "33",

pages = "2561--6",

journal = "Diabetes Care",

issn = "0149-5992",

publisher = "American Diabetes Association",

number = "12",

}

TY - JOUR

T1 - Osteoprotegerin and mortality in type 2 diabetic patients

AU - Reinhard, Henrik

AU - Lajer, Maria Stenkil

AU - Gall, Mari-Anne

AU - Tarnow, Lise

AU - Parving, Hans-Henrik

AU - Rasmussen, Lars Melholt

AU - Rossing, Peter

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Plasma osteoprotegerin (OPG) is an emerging strong and independent predictor of cardiovascular disease (CVD) in high-risk populations. OPG is a bone-related glycopeptide produced by vascular smooth muscle cells, and increased plasma OPG levels may reflect arterial vascular damage. We aimed to investigate the prognostic value of OPG in relation to all-cause and cardiovascular mortality in a cohort of type 2 diabetic patients.

AB - Plasma osteoprotegerin (OPG) is an emerging strong and independent predictor of cardiovascular disease (CVD) in high-risk populations. OPG is a bone-related glycopeptide produced by vascular smooth muscle cells, and increased plasma OPG levels may reflect arterial vascular damage. We aimed to investigate the prognostic value of OPG in relation to all-cause and cardiovascular mortality in a cohort of type 2 diabetic patients.

U2 - 10.2337/dc10-0858

DO - 10.2337/dc10-0858

M3 - Journal article

C2 - 20929997

SN - 0149-5992

VL - 33

SP - 2561

EP - 2566

JO - Diabetes Care

JF - Diabetes Care

IS - 12

ER -

Osteoprotegerin and mortality in type 2 diabetic patients

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater